YL-13027
Sponsors
Shanghai YingLi Pharmaceutical Co. Ltd., M.D. Anderson Cancer Center
Conditions
Advanced Solid TumorsMetastatic Pancreatic CancerSolid Tumor
Phase 1
First in Human Dose Escalation Study of YL-13027 in Subjects With Advanced Stage Solid Tumors
NCT03869632
Start: 2019-03-19End: 2022-06-30Target: 36Updated: 2021-11-16
YL-13027 in Patients With Advanced Solid Tumors
NCT05228600
Start: 2022-05-17End: 2023-12-01Target: 54Updated: 2022-05-20
A Trial of YL-13027 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Refractory Metastatic Pancreatic Cancer
TerminatedNCT06199466
Start: 2024-01-22End: 2025-09-15Updated: 2025-12-08
YL-13027 and/or HY-0102 Combined With AG Regimen Chemotherapy for Metastatic Pancreatic Cancer
Not yet recruitingNCT06662669
Start: 2024-11-30End: 2028-08-30Target: 120Updated: 2024-10-29